GSK to acquire Affinivax for $2.1B upfront to bolster vaccine portfolio

May 31, 2022 4:38 AM ETGSK plc (GSK)By: Ravikash, SA News Editor2 Comments

GSK, GlaxoSmithKline Headquarters, West London

Tati Campelo/iStock Editorial via Getty Images

GSK (NYSE:GSK) is acquiring Cambridge, Mass.-based pneumococcal vaccine maker Affinivax for a $2.1B upfront and up to $1.2B in potential development milestone payments.

Pneumococcal diseases include pneumonia, meningitis, bloodstream infections, sinusitis and otitis media, among others.


Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.